NEW YORK--(BUSINESS WIRE)---- $CNC #CNC--Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Centene Corporation ("Centene†or the "Company†) (NYSE: CNC) and reminds investors of the September 8, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm. ...

NEW YORK , Sept. 8, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Centene Corporation (NYSE: CNC). ...

Core Viewpoint - A class action lawsuit has been filed against Centene Corporation for allegedly misleading investors regarding its revenue outlook and growth projections during the specified class period from December 12, 2024, to June 30, 2025 [1][3]. Group 1: Lawsuit Details - The lawsuit is on behalf of all individuals and entities that purchased Centene securities during the class period [1]. - Investors have until September 8, 2025, to apply to the Court to be appointed as lead plaintiff in the lawsuit [1]. Group 2: Allegations Against Centene - The complaint alleges that Centene created a false impression of having reliable information about its projected revenue and growth while promoting enrollment rates and low morbidity [3]. - On July 1, 2025, Centene withdrew its 2025 guidance, revealing that its market growth across 22 states was lower than expected, leading to a reduction in guidance to approximately $1.8 billion or an adjusted diluted EPS of $2.75 [4]. - Following this announcement, Centene's stock price dropped from $56.65 per share to $44.78 per share, a decline of over 40% [4].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Centene Corporation due to misleading statements regarding the company's enrollment and morbidity rates, which led to a significant decline in stock price [4][6]. Group 1: Legal Investigation - Faruqi & Faruqi is reminding investors of the September 8, 2025 deadline to seek the role of lead plaintiff in a federal securities class action against Centene [4]. - The firm has a history of recovering hundreds of millions of dollars for investors since its founding in 1995 [5]. Group 2: Company Performance and Stock Impact - Centene provided positive statements while concealing adverse facts about its enrollment and morbidity rates, leading to investor skepticism [6]. - On July 1, 2025, Centene withdrew its 2025 guidance, stating that its market growth across 22 states was lower than expected, resulting in a revised guidance of approximately $1.8 billion or an adjusted diluted EPS of $2.75 [6]. - Following this announcement, Centene's stock price plummeted from $56.65 per share to $33.78 per share, marking a decline of 40.4% [7].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Centene Corporation securities between December 12, 2024, and June 30, 2025, of the September 8, 2025, deadline to become lead plaintiffs in a class action lawsuit [1]. Group 1: Class Action Details - Investors who bought Centene securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and interested parties must move the Court by September 8, 2025, to serve as lead plaintiff [2]. - The lawsuit alleges that Centene's management provided misleading information regarding the company's revenue guidance and earnings per share for the 2025 fiscal year, while concealing adverse facts about enrollment and morbidity rates [4]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting its own achievements in this area [3]. - The firm has secured significant settlements for investors, including over $438 million in 2019 alone, and has been consistently ranked among the top firms for securities class action settlements since 2013 [3].

Core Viewpoint - A lawsuit has been filed against Centene Corporation and its senior executives for potential violations of federal securities laws, specifically under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, following misleading financial guidance and subsequent stock price decline [1][2][4]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Southern District of New York, titled Lunstrum v. Centene Corporation, et al., No. 25-cv-05659 [2]. - Investors have until September 8, 2025, to request to be appointed to lead the case [2]. Group 2: Company Background - Centene Corporation is a healthcare company that provides services to consumers enrolled in government-sponsored healthcare programs such as Medicaid and Medicare, as well as those purchasing insurance under the Affordable Care Act [3]. Group 3: Financial Guidance and Market Performance - On December 12, 2024, Centene announced financial guidance for fiscal year 2025, claiming stability in earnings despite challenges [4]. - The company increased its 2025 guidance on February 4, 2025, citing enrollment overperformance, and again on April 25, 2025, due to strong growth in enrollment and retention [4]. - Contrary to these claims, the market experienced lower than expected enrollment growth and increased morbidity rates [4]. Group 4: Stock Price Reaction - On July 1, 2025, Centene withdrew its previous guidance after an independent actuarial report revealed lower than expected market growth and higher morbidity rates in 22 of the 29 states it serves [5]. - Following this news, Centene's stock price plummeted by $22.87 per share, a decline of over 40%, from $56.65 on July 1, 2025, to $33.78 on July 2, 2025 [5].

Core Viewpoint - Centene Corporation is facing a securities fraud class action lawsuit due to significant revenue declines and misleading statements made by the company during the class period from December 12, 2024, to June 30, 2025 [1][3]. Group 1: Lawsuit Details - The lawsuit is based on allegations that Centene made materially false and misleading statements and failed to disclose adverse facts about its business and operations [3]. - Centene's stock price dropped by $22.87, or 40.4%, closing at $33.78 per share on July 2, 2025, following the announcement of the withdrawal of its 2025 financial guidance [2]. - The class period for the lawsuit is defined as December 12, 2024, to June 30, 2025, with a deadline of September 8, 2025, for investors to seek lead plaintiff status [4]. Group 2: Financial Impact - The revenue decline was attributed to a risk-sharing mechanism related to the Affordable Care Act marketplace, which showed lower-than-expected enrollment and increased market morbidity [2][3]. - The preliminary analysis indicated that over two-thirds of Centene's marketplace share was affected, leading to the misleading nature of the company's previous positive statements [3].

Core Viewpoint - A class action lawsuit has been filed against Centene Corporation for allegedly misleading investors about its revenue outlook and growth projections during the specified class period from December 12, 2024, to June 30, 2025 [1][3]. Group 1: Lawsuit Details - The lawsuit is on behalf of all individuals and entities who purchased Centene securities during the class period [1]. - Investors have until September 8, 2025, to apply to the Court to be appointed as lead plaintiff in the lawsuit [1]. Group 2: Allegations Against Centene - The complaint alleges that Centene created a false impression of having reliable information regarding its projected revenue and growth, while actual enrollment rates and morbidity were lower than expected [3]. - On July 1, 2025, Centene withdrew its 2025 guidance, revealing that its market growth across 22 states was lower than anticipated, leading to a reduction in guidance to approximately $1.8 billion or an adjusted diluted EPS of $2.75 [4]. Group 3: Stock Impact - Following the announcement of the revised guidance, Centene's stock price plummeted from $56.65 per share on July 1, 2025, to $44.78 per share on July 2, 2025, marking a decline of over 40% [4].

Core Viewpoint - A securities class action lawsuit has been filed against Centene Corporation for allegedly making false and misleading statements regarding its business operations and market performance during the specified class period from December 12, 2024, to June 30, 2025 [1][2]. Group 1: Allegations Against Centene - The lawsuit claims that Centene's management misrepresented the company's marketplace share, indicating lower-than-expected enrollment and increased market morbidity [2]. - It is alleged that the statements made by Centene regarding its business operations and prospects were materially false and lacked a reasonable basis throughout the class period [2]. Group 2: Lead Plaintiff Process - Investors in Centene have until September 8, 2025, to apply to be appointed as lead plaintiff representatives in the class action [3]. - The lead plaintiff will represent the interests of all class members and will select legal counsel to direct the litigation [3]. Group 3: Law Firm Information - Kessler Topaz Meltzer & Check, LLP is the law firm handling the case and has a reputation for prosecuting class actions and recovering significant amounts for victims of corporate misconduct [4].

Core Viewpoint - Centene Corporation is facing a class action lawsuit due to allegations of providing misleading statements regarding its enrollment and morbidity rates, which led to a significant decline in its stock price after the company withdrew its 2025 guidance [3][4]. Group 1: Allegations and Impact - The class period for the lawsuit is from December 12, 2024, to June 30, 2025 [3]. - The complaint alleges that Centene's management made overly positive statements while concealing material adverse facts about the company's performance [3]. - Following the withdrawal of 2025 guidance, Centene's stock price plummeted from $56.65 per share on July 1, 2025, to $33.78 per share on July 2, 2025, marking a decline of 40.4% [3]. Group 2: Financial Adjustments - Centene's preliminary analysis indicated that its overall market growth across 22 states was lower than expected, leading to a reduction in its previously issued guidance to approximately $1.8 billion, with an adjusted diluted EPS of $2.75 [3]. Group 3: Next Steps for Shareholders - Shareholders are encouraged to register for the class action by September 8, 2025, to potentially become lead plaintiffs and receive updates on the case [4]. - There is no cost or obligation for shareholders to participate in the case [4].